6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. (Q43784378)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

main subject

phase III clinical trial

0 references

1 reference

Nicole Tubiana Mathieu

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Xavier Pivot

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

0 references

6

Thomas Bachelot

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Gilles Romieu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Marc Debled

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Jean-Yves Pierga

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Pierre Kerbrat

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Alain Lortholary

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Marc Espié

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Pierre Fumoleau

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Daniel Serin

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Jean-Philippe Jacquin

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Christelle Jouannaud

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Maria Rios

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Sophie Abadie-Lacourtoisie

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Laurent Cany

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Stéphanie Catala

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

David Khayat

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Iris Pauporté

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Andrew Kramar

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

PHARE trial investigators

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

11 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

3 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

741-748

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

3 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970225-0

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970225-0

7 January 2021

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970225-0

7 January 2021

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970225-0

7 January 2021

Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970225-0

7 January 2021

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970225-0

7 January 2021

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970225-0

7 January 2021

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970225-0

7 January 2021

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970225-0

7 January 2021

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970225-0

7 January 2021

Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970225-0

7 January 2021

10.1016/S1470-2045(13)70225-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23764181%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference